Sign in
AD

Alexa Deemer

Biotechnology Equity Research Associate at Cantor Fitzgerald, L. P.

New York, NY, US

Alexa Deemer is a Biotechnology Equity Research Associate at Cantor Fitzgerald, specializing in covering the biotechnology sector with a focus on clinical-stage pharmaceutical and biopharma companies. She has been cited as covering companies such as ARS Pharmaceuticals, actively participating in earnings calls and industry analysis but has not yet established a public record for performance metrics or analyst rankings on platforms like TipRanks. Deemer began her tenure at Cantor Fitzgerald in recent years and has been engaged in research roles pertinent to the life sciences sector, though publicly available details on her previous experience and precise start date remain limited. Her professional credentials include the Associate designation and, based on regulatory filings, she is likely to hold the required FINRA securities licenses for this role.

Alexa Deemer's questions to Invivyd (IVVD) leadership

Question · Q3 2025

Alexa Diemer from Cantor Fitzgerald inquired about Invivyd's plans for PEMGARDA once the next-generation product, VYD2311, receives approval, specifically asking if the company intends to wind down PEMGARDA and over what timeframe. She also asked for clarification on the required coordination between CBER and CDER for the LIBERTY study.

Answer

Marc Elia, Chairman of Invivyd's Board of Directors, stated that Invivyd has no plans to actively sunset PEMGARDA, acknowledging its differentiated molecular properties despite potential scalability challenges. Regarding the LIBERTY study, Mr. Elia explained that the coordination between CBER and CDER is a logistical step due to differing legal responsibilities for therapeutic monoclonal antibodies (CDER) and prophylactic medicines (CBER), especially when combining them in a single study. He noted that this is an unusual but interesting study, and the company anticipates alignment on the study's nature and boundaries.

Ask follow-up questions

Question · Q3 2025

Alexa Diemer asked about Invivyd's strategy for Pemgarda once the next-generation product, VYD2311, receives approval, specifically inquiring if there are plans to wind down Pemgarda and over what timeframe. She also inquired about the necessary coordination between the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER) within the FDA for the Liberty study, given the study's unique design.

Answer

Marc Elia, Chairman of Invivyd's Board of Directors, stated that there are no current plans to actively sunset Pemgarda. He acknowledged that while Pemgarda has some limitations in scalability and accessibility, it remains a differentiated medicine at the molecular level. Regarding the FDA coordination, Mr. Elia explained that the need for dialogue between CBER and CDER arises from differing legal responsibilities for prophylactic medicines (CBER) and therapeutic monoclonal antibodies (CDER) when commingling them in a single study. He noted that this is primarily a logistical step for the FDA to support labeling language, not an indication of extraordinary risk.

Ask follow-up questions

Alexa Deemer's questions to Trevi Therapeutics (TRVI) leadership

Question · Q2 2025

Alexa Deemer from Cantor Fitzgerald asked which dose or doses from the CORAL trial the company plans to advance into the Phase 3 study for IPF cough.

Answer

James Cassella, Chief Development Officer, identified the 54mg BID dose as a "sweet spot" due to its strong performance across both primary and secondary endpoints. He confirmed that the 54mg BID dose will be a key dose taken forward into the Phase 3 program, subject to FDA alignment.

Ask follow-up questions

Alexa Deemer's questions to ARS Pharmaceuticals (SPRY) leadership

Question · Q4 2024

Alexa Deemer from Cantor Fitzgerald asked about the breakdown of the epinephrine market between direct-to-patient retail sales and sales to institutional entities like airlines and schools.

Answer

Richard Lowenthal, Co-Founder, President and CEO, and Eric Karas, Chief Commercial Officer, clarified that nearly all current neffy sales are through the retail channel. They noted that the institutional market, such as airlines and restaurants, represents a future growth opportunity not yet included in forecasts, with some entities waiting for the 1mg dose to become available before adoption.

Ask follow-up questions

Best AI for Equity Research

Performance on expert-authored financial analysis tasks

Fintool-v490%
Claude Sonnet 4.555.3%
o348.3%
GPT 546.9%
Grok 440.3%
Qwen 3 Max32.7%